BridgeMD
New treatment option for Aging
Official title Tirzepatide to Slow Biological Aging
ClinicalTrials.gov ID: NCT07220473
What this study is testing
What is Zepbound?
Zepbound is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for aging.
Also referred to as Tirzepatide.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This pilot clinical study aims to investigate the potential effects of tirzepatide on biological aging in older adults. In this novel study, 90 adults aged 55-70 years with an indication for tirzepatide weight-loss therapy will be randomized to receive either tirzepatide 2.5 mg subcutaneously (SC) weekly or no drug for 24 weeks, followed by 12 weeks off the drug.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 55 to 70
You may be able to join if
- Age 55-70 years
- BMI ≥ 30 kg/m² or ≥ 27 kg/m² if also with ≥ 1 weight-related comorbidity
- If taking anti-inflammatory or blood-pressure-/lipid-/glucose-lowering medications, no change in dose for ≥12 weeks prior to entry and no plans to...
- Willing and able to provide written informed consent and undergo all required study procedures
You likely can't join if
- BMI \>35 kg/m²
- Uncontrolled or end-stage, comorbid, cardiometabolic disease, in the opinion of the site investigator
- Significant neurocognitive impairment, in the opinion of the site investigator
- Current or planned use of medications for the treatment of obesity, or medications likely to cause significant changes in weight, during the study...
- Use of insulin
- Plans to newly engage in formal, intensive physical activity or diet (such as ketogenic or very low carbohydrate) programs during the study period
See the full eligibility criteria
- Age 55-70 years
- BMI ≥ 30 kg/m² or ≥ 27 kg/m² if also with ≥ 1 weight-related comorbidity
- If taking anti-inflammatory or blood-pressure-/lipid-/glucose-lowering medications, no change in dose for ≥12 weeks prior to entry and no plans to dose escalate for the study duration
- Willing and able to provide written informed consent and undergo all required study procedures
- BMI \>35 kg/m²
- Uncontrolled or end-stage, comorbid, cardiometabolic disease, in the opinion of the site investigator
- Significant neurocognitive impairment, in the opinion of the site investigator
- Current or planned use of medications for the treatment of obesity, or medications likely to cause significant changes in weight, during the study period (see prohibited medications, section 6.0)
- Use of insulin
- Plans to newly engage in formal, intensive physical activity or diet (such as ketogenic or very low carbohydrate) programs during the study period
- Active eating disorder
- Use of human growth hormone, tesamorelin, supraphysiologic testosterone or estradiol (stable doses for contraception, hypogonadism or other indications for exogenous sex steroid replacement therapy permitted) or...
- Active, severe delayed gastric emptying
- Prior bariatric surgery or major gastric surgery or plans for weight reduction surgery while on study
- Known diabetic retinopathy
- Personal or first-degree relative history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
- Untreated, poorly controlled or previously undiagnosed thyroid disease
- History of chronic pancreatitis
- History of suicidal attempts or active suicidal ideation, in the opinion of the site investigator
- Known allergy/sensitivity to GLP-1RA or GIPRA
- Use or planned use of any immunomodulatory therapy or investigational therapy during the study period or use of an investigational therapy within 30 days of entry
- Any other medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation.
- Pregnancy, nursing or plans for either during the study period
The study team makes the final eligibility decision.
Where it's taking place
- Galveston, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 55 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Galveston, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.